Clinical studies have shown that administration of angiotensin-converting-enzyme (ACE) inhibitor reversed proteinuria and CKD progression in patients with non-diabetic chronic nephropathy [101,102] and in diabetics [103]. This evidence concerns the gene ACE and chronic kidney disease.